InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
T+90 hit rate
50%
T+90 mean return
-2.4%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Maduck Sean, Directeur Commercial. Insider active across 2 companies, notably Corcept Therapeutics INC. Cumulatively, 55 disclosures have been published. Split: 0 buy · 7 sells. Total volume traded: €7.7m. Activity tracked since 7 July 2021. The latest transaction was disclosed on 1 July 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations55 total
25,000 shares@ US$8.27Common StockSEC:0001193125-26-296296:0
11,024 shares@ US$87.3349Common StockSEC:0001193125-26-296296:1
2,801 shares@ US$88.5127Common StockSEC:0001193125-26-296296:2
11,175 shares@ US$89.3094Common StockSEC:0001193125-26-296296:3
25,000 shares@ US$8.270.0029% mcap2.0% of flowCommon StockSEC:0001193125-26-256013:0
21,069 shares@ US$70.10680.021% mcap14.5% of flowCommon StockSEC:0001193125-26-256013:1
3,931 shares@ US$70.74620.0040% mcap2.7% of flowCommon StockSEC:0001193125-26-256013:2
615 shares@ US$70.440.0006% mcap0.4% of flowCommon StockSEC:0001193125-26-256013:3
615 shares0Common StockSEC:0001193125-26-256013:4
452 shares@ US$70.440.0005% mcap0.3% of flowCommon StockSEC:0001193125-26-256013:5
75,000 shares@ US$8.270.0088% mcap6.1% of flowCommon StockSEC:0001193125-26-248967:0
54,575 shares@ US$65.37110.051% mcap35.0% of flowCommon StockSEC:0001193125-26-248967:1
20,425 shares@ US$66.15990.019% mcap13.2% of flowCommon StockSEC:0001193125-26-248967:2
12,856 shares@ US$5.050.7% of flowCommon StockSEC:0000950170-25-063835:0
100,000 shares@ US$8.278.7% of flowCommon StockSEC:0000950170-25-049816:0
1,697 shares@ US$5.050.1% of flowCommon StockSEC:0000950170-25-045431:0
228 shares@ US$60.580.2% of flowCommon StockSEC:0000950170-25-032789:0
11,986 shares@ US$3.880.5% of flowCommon StockSEC:0000950170-25-014463:0
20,000 shares@ US$3.880.9% of flowCommon StockSEC:0000950170-25-002466:0
295 shares@ US$57.680.2% of flowCommon StockSEC:0000950170-24-133444:0
232 shares@ US$35.300.1% of flowCommon StockSEC:0000950170-24-104199:0
823 shares@ US$30.170.3% of flowCommon StockSEC:0000950170-24-069604:0
50,000 shares@ US$3.882.1% of flowCommon StockSEC:0000950170-24-060767:0
25,953 shares@ US$3.881.1% of flowCommon StockSEC:0000950170-24-038530:0
17,219 shares@ US$3.880.7% of flowCommon StockSEC:0000950170-24-034264:0
25 of 55 declarations
About Maduck Sean
Sean Maduck is tied to Corcept Therapeutics, where he has served as President, Endocrinology since 2022. Corcept says he joined the company in 2012 after 12 years of experience in finance, biotechnology, and management at Genentech, and earlier as an investment banking analyst at W.R. Hambrecht + Company. The company also says he serves on the board of the Cancer Support Community, San Francisco Bay Area. Sources : https://corcept.com/about/teams/sean-maduck/
